These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19697757)

  • 1. Addressing supply side barriers to introduction of new vaccines to the developing world.
    McElligott S
    Am J Law Med; 2009; 35(2-3):415-41. PubMed ID: 19697757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
    Crager SE
    Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways.
    Crager SE
    Am J Public Health; 2014 Nov; 104(11):e85-91. PubMed ID: 25211753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affordably priced new drugs for poor populations: Approaches for a global solution.
    Mossialos E; Dukes G
    Int J Risk Saf Med; 2001; 14(1):1-29. PubMed ID: 22388482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines as a global imperative--a business perspective.
    Stéphenne J
    Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market.
    Nakakeeto ON; Elliott BV
    Global Health; 2013 Feb; 9():6. PubMed ID: 23410145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
    Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
    Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The global capacity for manufacturing vaccines. Prospects for competition and collaboration among producers in the next decade.
    Robbins A; Arita I
    Int J Technol Assess Health Care; 1994; 10(1):39-46. PubMed ID: 8157459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
    Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
    Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market-based licensing for HPV vaccines in developing countries.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Children's Vaccine Initiative and vaccine supply: the role of the public sector.
    van Noort RB
    Vaccine; 1992; 10(13):909-10. PubMed ID: 1471410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Setting prices for new vaccines (in advance).
    McGuire TG
    Int J Health Care Finance Econ; 2003 Sep; 3(3):207-24. PubMed ID: 14626000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WHO expectation and industry goals.
    Vandersmissen W
    Vaccine; 2001 Feb; 19(13-14):1611-5. PubMed ID: 11166883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature.
    Arango-Luque A; Yucumá D; Castañeda CE; Espin J; Becerra-Posada F
    Value Health Reg Issues; 2024 Jul; 42():100981. PubMed ID: 38677063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.